

Hisamitsu Pharmaceutical Co., Inc. Q2 FY02/2009 Results

This presentation material contains information that constitutes forward-looking statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors including changes in material circumstances.

Oct 9th, 2008

Patch and Care of People around the World

Copyright© 2005 Hisamitsu. All right reserved.

Consolidated P/L

Alisamitsu

Net Sales: ¥63,578mn (+5.2% YoY)

CoGS: ¥20,01<mark>9mn (+11.9% YoY)</mark>

SG&A costs: ¥26,606mn (△6.3% YoY)

Operating income: ¥16,952mn (+19.9% YoY)


Nonoperating income: ¥629mn

Recurring profits: ¥17,582mn (+20.2% YoY)

Extraordinary income: ¥1,336mn

Tax adjustment: △¥7,699mn

Net income: ¥11,219mn (+26.6% YoY)



Patch and Care of People around the World

Copyright© 2005 Hisamitsu. All right reserved.

3

Core product sales

Alisamitsu

(Unit: ¥mn)

	Q2FY2/09	YoY change (%)	FY2/09 Target	Targeted YoY increase
Mohrus tape	35,492	+ 10.9%	72,000	+ 10.3%
(Mohrus Tape L)	15,014	+ 26.2%	31,000	+ 22.9%
Mohrus	6,301	<i>△ 6.7%</i>	12,500	<i>△ 3.7%</i>
Naboal	1,007	<i>△ 8.3%</i>	2,000	<i>△ 3.5%</i>
Inside Pap	517	<i>△ 14.8%</i>	850	<i>△ 26.5%</i>
Salonpas	3,677	+ 0.5%	7,200	+ 4.3%
Salonsip	2,344	△ 0.9%	4,200	+ 0.3%
Air-Salonpas	1,604	+ 38.5%	2,100	+ 19.2%
Butenalock	1,389	<i>△ 4.3%</i>	2,300	<i>△ 10.1%</i>
Feitas	2,103	<i>△ 3.3%</i>	4,500	+ 11.3%

Alisamitsu

Summary of Profit and Loss (Y o Y)

- Sales: +5.2%
 - Rx Business Div.: Favorable transition of sales of Mohrus Tape and Mohrus Tape L
- Cost of sales: +11.9%
 - National Health Insurance price reduction rate of hisamitsu: 3.9%
 - New plants operation at Tosu factory (November 2007 \sim),new production line operation for FS-67 approved by U.S.FDA,change of depreciation rule
- Sales management expense: +1.2%
 - R&D cost ⇒ Presence of new commodity introduction cost
- Nonoperating, Extraordinary balance: +202.1%
 - Upfront and mileston payments for out-licensing of HFT-290
 - Increase of dividend due to liquidation of an affiliated company (consolidated setoff)
 - Reversal of allowances in relation to subsidiary companies (consolidated setoff)


Patch and Care of People around the World Copyright© 2005 Hisamitsu. All right reserved.

5

The second generation anti-inflammatory analgesic patches market in Japan (Quantity)




Source: IMS JPM



Domestic market share





R&D Pipeline

Alisamitsu

Stage	Theme	Country	Dosage form	Characteristics	Next step
Filed	SG-01	J	Patch	Bedsores, etc. (Medical equipment)	Planned approval in FY08
Filed	HFT-290	J	Patch	Alleviation of cancer pain	Planned approval in FY09
Filed	KPT-220	7	Patch	Relief of pain in rheumatoid arthritis	Planned approval in FY10
Filed	HFG-512	US	Patch	Alleviation of moderate to severe chronic pain	Nondisclosure of information
Filing being prepared	BTDS (obtained exclusive sales rights in Japan from Mundipharma K.K.)	J	Patch	Alleviation of non-cancer pain	Filed in FY08
РШ	HKT-500	US	Patch	Short term management of mild to moderate localized pain	Filed in FY10
PΙ	HTU-520	J	Patch	Tinea unguium	PⅢ in FY10
РⅡ	HOB-294	J	Patch	Overactive bladder	PⅢ in FY10

^{*} Yellow-highlighted parts are changes from the previous announcement made on July 1.

- KPT-220 (Japan: Alleviation of pain in rheumatoid arthritis)
 - Although the application was filed in September 07, anticipated to be approved in FY10, because the reviews of Ministry of Health, Labour and Welfare are congested.
- HFG-512 (US: Alleviation of moderate to severe chronic pain)
 - Along with changes in the label of a branded product, a clinical trial has been required additionally.
 - Because of competitive nature of GE market, expected approval date is subject to being non-disclosed.

Patch and Care of People around the World Copyright© 2005 Hisamitsu. All right reserved.

q

Progress of Clinical Trials

Alisamitsu

- HKT-500 (US: Alleviation of joint pain, low back pain and myalgia)
 - The clinical study for pain in OA knee did not show significantly statistical difference from placebo.
 - Other two clinical trials (pain in shoulder and ankle) are implemented.
 - Application planned to be filed in FY10.
- HOB-294 (Japan: Overactive bladder)
 - Although its clinical development program has been suspended in FY05, at the end of P1, we have resumed the program from P2 because of its marketability.
 - PIII study will be started in FY10.

"Improving Quality of Life (QOL) for People in the World"

Oct 9th, 2008

Patch and Care of People around the World
Copyright© 2005 Hisamitsu. All right reserved.